VBL Therapeutics closes merger with Notable Labs, to begin trading under ‘NTBL’

Notable Labs, a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, announced the completion of its merger transaction with VBL Therapeutics (VBLT) and associated financing. The combined company will focus on the advancement of Notable’s proprietary Predictive Precision Medicines Platform, or “PPMP,” and therapeutic pipeline focused on cancer patients with high unmet medical needs while completing the development of Volasertib for the treatment of acute myeloid leukemia, or AML, in platform-predicted responders as the flagship program. The ordinary shares of the combined company, renamed Notable Labs, are expected to commence trading on The Nasdaq Capital Market, on a 1-for-35 reverse split basis, under the ticker symbol “NTBL” and a new CUSIP number at the open of market trading on October 17, the company stated. “This is an important milestone for Notable as we continue to advance the demonstrated value of the PPMP. The merger will add additional capital to accelerate our continued development of Volasertib for the treatment of AML in PPMP-predicted responding patients. As a publicly traded company, we will continue to evaluate potential additional programs and assets where PPMP is especially suited for risk-reducing and fast-tracking therapeutic development,” said Thomas Bock, M.D., Chief Executive Officer of Notable.